Avicanna provides update on the successful launch of MyMedi.ca

(Globe Newswire) Toronto — Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased provide an update on the progress of its new cannabis care platform MyMedi.ca since its’ successful launch nationwide in Canada on August 1, 2023.

“We are thrilled with the launch of our new medical cannabis care platform which allowed us to successfully transition the patients from Medical Cannabis by Shoppers. In a short period of time, MyMedi.ca has been established as a comprehensive medical cannabis platform with a robust patient support program backed by privacy standards that meet the highest requirements by insurers for insurance coverage for patients” said Aras Azadian, CEO.

Azadian further stated: “Our ongoing commitment to patients and dedication to improving the patient journey remains our core focus and we will continue to work toward raising standards so Canadians may look towards having a patient-first medical cannabis care platform.”

The company update on the progress of its new medical cannabis care platform, MyMedi.ca, includes:

Advertisement

— Transition of over 96 per cent of active patients from Medical Cannabis by Shoppers to MyMedi.ca and an increase of approximately 10 per cent of net new medical patients since launch.

— Developed infrastructure to offer insurance reimbursement services for patients through several private insurance providers and public institutions including six provincial worker safety boards.

— Offer ongoing specialty care services for distinct patient groups and the opportunity to serve thousands of our Canada’s veterans with a dedicated program including robust adjudication services.

— An established network of over 50 specialized clinics and medical institutions representing more than 1,500 healthcare providers.

— Offer training, medical education, products and services, and resources to facilitate the incorporation of medical cannabis into health care regimens including the company’s own Avicenna Academy and the Canadian Consortium for the Investigation of Cannabinoid Syllabus.

— An opening portfolio of 200 products across 35 brands, expanding to 45 brands with more than 200 SKUs supplied by 15 Canadian licensed producers.

— Since launch, an increase in the Company’s SKUs resulting in a proportional increase of 40 per cent in sales realized through improved access, and inventory management efficiencies.

— Facilitation of transfer and advancement of the Company’s previously announced real world evidence clinical studies, including the epidermolysis bullosa study in collaboration with the Hospital for Sick Children and musculoskeletal pain and inflammation study with Sante Cannabis, to MyMedi.ca

— Enhanced operational efficiencies in reducing response time and expanding pharmacist-led, bilingual patient care services.

Village Farms International and executives recognized for cannabis industry contributions

(Globe Newswire) Vancouver — Village Farms International, Inc. announced the recognition of two executives for their industry contributions. President and chief executive officer, Michael DeGiglio, has been named a 2023 Notable Leader in cannabis by Green Market Report, an aggregator of financial news and analytics for the cannabis industry.

John Harloe, J.D., Ph.D., General Counsel at Village Farms’ wholly owned subsidiary, Balanced Health Botanicals, has been appointed to the governing board of Colorado’s Institute of Cannabis Research (ICR). The company was also honored, for the second consecutive year, as the Best Canadian Cannabis Company at the 2023 Benzinga Cannabis Awards.

Michael DeGiglio named Notable Leader in Cannabis for 2023

DeGiglio is among 75 Notable Leaders in Cannabis that according to Green Market Report “have demonstrated a willingness to effect meaningful change in a dynamic industry. Their innovation, drive, and leadership help move the market forward while navigating a wide range of challenges thrown in their directions.”

Advertisement

Green Market Report’s Notable Leaders in cannabis is part of a time-honored Crain Communications’ program that recognizes leaders across a range of industries for their success and accomplishments, both in their field and in their communities. The Notable program began in 2017 and has recognized more than 5,000 leaders in Chicago, Cleveland, Detroit, Grand Rapids, and New York — and now nationally for the cannabis industry. The cannabis industry honorees include plant-touching and non-plant-touching companies from across the cannabis world.

John Harloe appointed to governing board of Colorado Institute for Cannabis Research

As a member of Colorado’s Institute of Cannabis Research Governing Board, Harloe will serve as a representative of the cannabis industry, deploying his extensive scientific, regulatory and legal experience in support of its role and mission to conduct or fund research related to cannabis and publicly disseminate the results of the research, as well as to advise any Colorado institution of higher education developing a cannabis-related curriculum and provide input to the Colorado Commission on Higher Education before approving any cannabis-related degrees or certifications.

Harloe has been General Counsel of Balanced Health Botanicals since January 2019, a month after the 2018 Farm Bill was passed. In 2022, he was appointed by the state to serve on Colorado’s SB22-205 Task Force to develop regulations on intoxicating hemp products.

Village Farms named Best Canadian Cannabis Company at 2023 Benzinga Cannabis Awards

Village Farms was named the Best Canadian Cannabis Company at the 2023 Benzinga Cannabis Awards, the second consecutive year that the company has received this award. The Benzinga Cannabis Awards “celebrate the new, creative, innovative, and outstanding of the cannabis industry, spotlighting the industry’s luminaries, from trailblazers and innovators to advocates who are helping to advance all facets of the business.” The awards were announced during the Benzinga Cannabis Capital Conference in Chicago on September 27.

Cannabis Act review finds companies struggling to profit, health experts supportive

OTTAWA — A review of the federal legislation that paved the way for the legal recreational use and sale of cannabis says companies in the legal market report struggling to realize profits and maintain financial viability.

Retailers cite the burden of taxes, markups, fees, and regulatory compliance costs as barriers to the industry’s viability, which they say is a necessary precondition to maintaining a safe and legal source of supply and to combat the illicit market.

The statutory review was launched by the federal government last year to analyze the Cannabis Act, which in 2018 set purchase and possession limits at 30 grams of dried pot or the equivalent, restricted youth access to marijuana and established safety requirements for growing, selling and transporting the substance.

The report says public health experts remain supportive of the legislation’s precautionary approach, including THC limits for edible cannabis products and restrictions on promotion, while some suggest considering stricter age limits on who can possess, distribute and buy cannabis.

Advertisement

While the panel that conducted the review says it heard progress has been made on deterring criminal activity and displacing the illicit market, many public safety stakeholders remain concerned about unauthorized retail stores and illegal online channels.

Panellists heard varying viewpoints on whether consumer demand was being met, with consumers still seeking products unavailable in the legal market such as higher-potency edibles, along with limited access in some rural and remote regions.

The Cannabis Act review will not save your business 

The Cannabis Act review will not save your business 

Speaking with people in the industry, I’m always struck by how often I hear references to the current review of the Cannabis Act as something they expect to bring economic relief to the industry. 

While that would be a welcome evolution, in my opinion, it’s not a wise place to place one’s hopes. While there may very well be some regulatory changes that come out of the current legislative review of the federal Cannabis Act, the review itself is legislative, not regulatory. 

When the Cannabis Act was written, there were many concerns about the possible impact on Canadian society. There were many concerns from some segments of Canada that worried legal cannabis would mean young people would have easier access, which would make it even more likely for them to try cannabis, or that allowing home cultivation of cannabis would lead to a rash of home fires and mouldy basements. Similarly, many First Nations and other Indigenous leaders told the government they were concerned about the negative impacts of cannabis in their communities, many of which were and are already “dry” to alcohol sales and even consumption. 

Because of these concerns, the Cannabis Act had a review built into it, calling on the government to investigate the progress of legalization and its impacts on these three key issues. 

From the Act:

Review of Act

  • 151.1 (1) Three years after this section comes into force, the Minister must cause a review of this Act and its administration and operation to be conducted, including a review of the impact of this Act on public health and, in particular, on the health and consumption habits of young persons in respect of cannabis use, the impact of cannabis on Indigenous persons and communities, and the impact of the cultivation of cannabis plants in a dwelling-house.

This review, which was supposed to begin by October 2021 but began a full year behind schedule, is supposed to culminate in a report to be tabled by both Houses of Parliament within 18 months of the review’s launch, which would be early 2024. 

This report will not necessarily result in every proposal or statement resulting in any legislative or regulatory change. It’s simply to provide information that serves to answer the three key questions as to the impact of legalizing cannabis on Canadian society, namely young people, Indigenous communities, and people’s homes. 

Any changes resulting from the report will still be required to go through Health Canada rather than the report serving as a specific mandate. 

In addition, it’s important to understand the difference between a legislative review and a regulatory review. Cannabis in Canada is built around two key documents: the Cannabis Act, and the Cannabis Regulations that the Act empowers.

While the Cannabis Act deals with things such as prohibitions, obligations, and offences, the Cannabis Regulations deal with things like federal production and research licences, rules for how producers must operate, subcategories of products like edibles or extracts, etc. Specific industry hot topics, like the high rate of the excise tax or the low 10 mg limit for edibles, are informed by the Regulations, not the Act. 

That isn’t to say that the current review of the Act won’t result in any regulatory changes. It very well may. Regulatory changes tend to be ongoing, with an array of changes in the last five years, from more significant changes like the planned addition of edibles, extracts, and topicals, to changes such as allowing processors to be automatically issued a sales amendment for dried cannabis, or an array of changes during covid to streamline producer activities. 

So there is little reason to think that the report to be tabled in the House of Commons by next Spring (assuming they stick to the stated timeline) won’t include any regulatory changes—but keep your expectations tempered. While industry wants (and needs) sweeping changes, but don’t count on it.

Related Articles

What is the status of the Review?

In late 2022, Health Canada announced the members of the independent five-person expert panel to lead a review of the Cannabis Act, with experts from public policy, public health, First Nations, and criminal law backgrounds. 

The panel’s work is divided into two phases. The first is a “factual assessment” of the impacts of the Cannabis Act, informed by the results of a recent public engagement process that ended in November 2022. Health Canada has an additional engagement process for First Nations, Inuit, and Métis peoples that was extended until January 15, 2023.

The expert panel released their What We Heard Report on October 10, which emphasized the public health lens the review is going through, while also acknowledging feedback from industry calling for more substantive regulatory changes.

The second phase of the panel’s work will focus on providing advice to the government on what aspects of the legislative (note: not regulatory) framework, or its implementation, can be improved or reformed. 

The expert panel has also been crisscrossing the country, meeting with a wide array of stakeholders, from First Nations and activist groups to small and large cannabis businesses, medical and public health experts, law enforcement, various political representatives at all levels of government, and more. 

This process will be used to inform the report eventually tabled in Parliament. 

In addition, the review process includes a yet-to-be announced expert advisory panel made up of industry stakeholders. Although no official list of names has been released yet, some media and others in the industry have noted it reportedly has several high-level executives from large, publicly traded cannabis companies, and has not been meeting consistently.  

Where do we go from here?

Lobbying the government for regulatory changes is an ongoing process, and the Canadian cannabis industry has a varied track record in that regard, some successful, others not so much. The ongoing Cannabis Act review absolutely provides a rallying point for industry to highlight many ongoing issues and concerns, such as high taxes and edibles potency limits, and industry has been making full use of that. 

However, I worry that many have bought into a narrative that major regulatory changes are coming soon as a result of this review. Changes that will “save” the industry. And I have to say, if you are waiting for the government to come swooping in to save this industry, you’re waiting for Godot. 


420 with CNW — Florida Supreme Court Sets Date to Decide Cannabis Ballot Measure’s Fate

420 with CNW — Florida Supreme Court Sets Date to Decide Cannabis Ballot Measure’s Fate

image

The Florida Supreme Court has set dates for oral arguments in a case that will determine if a state cannabis legalization measure appears on the 2024 ballot. Both the Smart & Safe Florida campaign, which sponsored the cannabis legalization proposal, and the state attorney general have spent the past few months sending briefs to Florida’s Supreme Court.

Florida Attorney General Ashley Moody filed a challenge against the proposal and called for its invalidation on the grounds that it is misleading. She argued in her challenge that the measure was ‘”effectively misleading” because it doesn’t explicitly state that marijuana will still be illegal under federal law even if Florida amends its law to legalize the plant.

While the Smart & Safe Florida campaign noted that it was incredulous to think any American was unaware of marijuana’s controlled status at the federal level, the attorney general’s office argued that most Americans are too ignorant of state and federal policies to know. Furthermore, Moody’s office said the proposal was written in a way that would provide an unfair advantage to marijuana company Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), the campaign’s primary financial backer.

The challenge claimed that the proposal’s ballot summary was misleading in subtle but influential ways, stating that Truelieve was inviting millions of Florida residents to join in its “reckless violation of federal criminal law” in its pursuit of larger markets and bigger profits.

Moody said the measure was also “duping voters” by saying it would increase cannabis retailers in the state when it would only authorize the expansion of the state’s cannabis retailer base, no doubt hoping to appeal to Floridians who were interested in accessible medical marijuana treatment centers.

A brief from the Drug Free America Foundation noted that the measure was in positive conflict with federal law and violated the U.S. Constitution’s supremacy clause, which states that federal law generally supersedes state laws and constitutions. Furthermore, the Florida Chamber of Commerce submitted a brief to the state Supreme Court noting that the cannabis legalization proposal was in constitutional violation of the single-subject rule for ballot proposals. The Chamber of Commerce also supported Moody’s argument that the ballot’s title and summary language were misleading.

On the other hand, Smart & Safe Florida and cannabis reform supporters argue that Floridians should have the chance to decide on cannabis reform after they submitted close to a million certified signatures.

The Supreme Court has scheduled the next hearing for key arguments and responses from the attorney general and Smart and Safe Florida to Nov. 8, 2023.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

BC First Nation utilizing new “sovereign” edibles store next to their own provincially-licensed retail store

BC First Nation utilizing new “sovereign” edibles store next to their own provincially-licensed retail store

image

A First Nations-owned cannabis producer and retailer is now taking what they say is a “hybrid approach” to cannabis sales on their reserve lands.

Williams Lake First Nation (WLFN) is the signatory of the first government-to-government agreement with the Province of British Columbia under section 119 of BC’s Cannabis Control and Licensing Act and owns and operates cannabis retailer Unity Cannabis as well as the cannabis producer and brand Sugar Cane Cannabis on WLFN reserve land on a large lot just south of downtown Williams Lake. The two businesses share a large parking lot. 

The First Nation also recently opened a new retail store in that same parking lot that sells edibles that are otherwise not available through the BC LDB’s supply chains. Kirk Dressler, the Director of Legal and Corporate Services with the Williams Lake First Nation and the CEO of Unity Cannabis and Sugar Cane Cannabis, says the new “hybrid” retail model is one born of both economic necessity, and as a response to a recent BC court ruling.

According to Dressler, the new store will initially carry a limited selection of edibles that have demand in the WLFN community and in other indigenous communities. He also decries the amount of plastics and other packaging required for edibles under the federal regulations, saying that the products sold at the WLFN sovereign store seek to address the issue.

From an economic standpoint, Dressler says both Sugar Cane and Unity Cannabis are facing challenges, with slim profit margins and increasing price compression, making it difficult to compete. WLFN has engaged the province on the issue multiple times to address the issue, and to push the government on the Cannabis-related commitments in its DRIPA Action Plan, but Dressler says the response from the government has not been satisfactory. 

Since the province has in the past said they are not seeking to actively enforce their own provincial retail rules on First Nations land, WLFN is utilizing this new “hybrid” retail space to exercise what they say is their sovereign right to sell cannabis on their own land without provincial oversight. 

“WLFN is in a position where it might be one of those that is forced to exit [the industry],” Dressler explains. “That is not acceptable. We’ve invited the province to look at fair and reasonable solutions. The province has refused to collaborate in any meaningful way, despite the fact the province has an obligation under DRIPA to do so and has agreed that it must do so. We’ve advised them that this leaves us with no option but to contemplate what steps we can take to utilize our jurisdiction to make our operation more viable. The province has nodded their head and acknowledged that that seems to be a reasonable response. That’s the inference we’ve drawn. So, we are in fact proceeding to do so.”

He says WLFN is taking steps to ensure they are still adhering to the rules of their Section 119 agreement, and the Unity Cannabis and Sugar Cane Cannabis operations are entirely unaffected by the establishment of the new store. . 

“What we are contemplating at this point is a hybrid system that would continue to respect the commitments we have in our 119 agreement but it would also allow Williams Lake First Nation to utilize its jurisdiction to develop a cannabis-related enterprise that might generate revenue sufficient to sustain our global cannabis operation.”

The store bills itself as an “edibles store” and promises the “cheapest edibles in town”. Dressler says all products sold within the store will come with COAs.

420 with CNW — Florida Supreme Court Sets Date to Decide Cannabis Ballot Measure’s Fate

420 with CNW — Could Marijuana Rescheduling Result in Nationwide Legalization?

image

The discussion surrounding the legalization of cannabis has remained a prominent topic in recent times, with several states choosing to take matters into their own hands by legalizing it within their borders rather than waiting for federal intervention. However, there is now a glimmer of hope on the federal front as health officials have recommended marijuana reclassification, potentially signaling a significant stride toward nationwide legalization.

Unfortunately, this isn’t as straightforward as it may appear.

Currently, marijuana is categorized as a Schedule I drug, a classification that implies the DEA deems it as lacking a recognized medical purpose and having a substantial potential for abuse. However, the United States Department of Health and Human Services shared its findings on cannabis with the U.S. Drug Enforcement Administration (DEA) and recommended that it be classified as a Schedule III substance. According to this classification, the drug has a low to moderate risk of causing physical and mental dependence. Comparable drugs in Schedule III include anabolic steroids and ketamine.

While the recommendation may sound promising, the status quo for marijuana remains largely unaffected. The DEA will require a considerable amount of time to deliberate and decide on the reclassification. In addition, even if reclassified, cannabis would still fall under the purview of federal regulations, remaining a controlled substance. Importantly, it does not instantaneously translate into federal legalization for recreational use and does not decriminalize the substance.

Nevertheless, the reclassification of cannabis could bring about some positive changes. For example, it would pave the way for increased research opportunities since studying Schedule III drugs is less restrictive compared to Schedule I. Additionally, it might lead to a reduction in the federal taxes levied on cannabis businesses. Under the current tax code, enterprises dealing with Schedule I and II substances cannot claim deductions for expenses such as payroll or rent, resulting in high tax rates for cannabis companies.

Presently, about 23 states have legalized recreational cannabis, while 38 states have legalized it for medical purposes. The latest additions to this list are Missouri, Maryland, Connecticut, New York and Rhode Island.

The potential repercussions of cannabis reclassification in these states remain uncertain. Natacha Andrews, who serves as the executive director of the National Association of Black Marijuana Lawyers, suggests that it could potentially disrupt state programs, stating, “The state-level legalization goes against the established order. The ambiguity surrounding the DEA’s next steps raises numerous questions, with some states experiencing minimal disruptions while others encounter more significant issues.”

The cannabis industry, together with its leading enterprises such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), would appreciate cannabis policy reforms at the federal level that ease some of the complications companies have to navigate as they stay compliant with state law while also keeping federal law in mind.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN